CN116616444A - 具有改善抑郁情绪与压力应激作用的药食两用组合物及其制备方法与应用 - Google Patents
具有改善抑郁情绪与压力应激作用的药食两用组合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN116616444A CN116616444A CN202310665610.2A CN202310665610A CN116616444A CN 116616444 A CN116616444 A CN 116616444A CN 202310665610 A CN202310665610 A CN 202310665610A CN 116616444 A CN116616444 A CN 116616444A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- depression
- weight
- stress
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 239000003814 drug Substances 0.000 title claims abstract description 45
- 230000000694 effects Effects 0.000 title claims abstract description 40
- 235000013305 food Nutrition 0.000 title claims abstract description 29
- 230000008451 emotion Effects 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title abstract description 16
- 230000000994 depressogenic effect Effects 0.000 title abstract description 11
- 230000009977 dual effect Effects 0.000 title description 8
- 238000004519 manufacturing process Methods 0.000 title description 3
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 34
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 20
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 20
- 235000008434 ginseng Nutrition 0.000 claims abstract description 20
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 18
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 18
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 18
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 18
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 17
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 17
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 17
- 241000237502 Ostreidae Species 0.000 claims abstract description 17
- 241000220317 Rosa Species 0.000 claims abstract description 17
- 235000020636 oyster Nutrition 0.000 claims abstract description 17
- 229960003080 taurine Drugs 0.000 claims abstract description 17
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 230000036541 health Effects 0.000 claims abstract description 6
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 5
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 5
- 235000001188 Peltandra virginica Nutrition 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 241000208340 Araliaceae Species 0.000 claims description 19
- 241000723353 Chrysanthemum Species 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 16
- 244000197580 Poria cocos Species 0.000 claims description 15
- 210000000582 semen Anatomy 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 6
- 206010012374 Depressed mood Diseases 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- -1 decoction Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 4
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 42
- 230000035882 stress Effects 0.000 description 21
- 210000004185 liver Anatomy 0.000 description 20
- 210000003734 kidney Anatomy 0.000 description 17
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 16
- 210000004556 brain Anatomy 0.000 description 15
- 230000007812 deficiency Effects 0.000 description 15
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 14
- 230000037326 chronic stress Effects 0.000 description 14
- 229960002464 fluoxetine Drugs 0.000 description 14
- 238000012360 testing method Methods 0.000 description 12
- 108010025020 Nerve Growth Factor Proteins 0.000 description 11
- 239000002858 neurotransmitter agent Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000000971 hippocampal effect Effects 0.000 description 7
- 230000009182 swimming Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 6
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 102000015336 Nerve Growth Factor Human genes 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 229940053128 nerve growth factor Drugs 0.000 description 6
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 6
- 229960002748 norepinephrine Drugs 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 5
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 102000007072 Nerve Growth Factors Human genes 0.000 description 5
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 5
- 208000037977 central nervous inflammation Diseases 0.000 description 5
- 230000009990 central nervous inflammation Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000003900 neurotrophic factor Substances 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 230000007267 depressive like behavior Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000004295 hippocampal neuron Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000002442 prefrontal cortex Anatomy 0.000 description 2
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 230000003956 synaptic plasticity Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 101000831205 Danio rerio Dynein axonemal assembly factor 11 Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 102100024282 Dynein axonemal assembly factor 11 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000018779 Globus Sensation Diseases 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241001559542 Hippocampus hippocampus Species 0.000 description 1
- 101000831210 Homo sapiens Dynein axonemal assembly factor 11 Proteins 0.000 description 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- LZCZIHQBSCVGRD-UHFFFAOYSA-N benzenecarboximidamide;hydron;chloride Chemical compound [Cl-].NC(=[NH2+])C1=CC=CC=C1 LZCZIHQBSCVGRD-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 210000003520 dendritic spine Anatomy 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960000450 esketamine Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000001153 interneuron Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000002314 neuroinflammatory effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 1
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 1
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种具有改善抑郁情绪与压力应激作用的药食两用组合物及其制备方法和应用,它由下列重量份数的原料制成:牡蛎1~10份,陈皮0.5~5份,茯苓0.5~5份,人参0.1~1份,玫瑰花0.2~2份,黄精0.5~5份,枸杞子0.5~5份,决明子0.5~5份,菊花0.5~5份,磷脂酰丝氨酸0.01~0.1份,牛磺酸0.01~0.1份。本发明提供的药食两用组合物,可改善抑郁情绪与压力应激,可用于制备抗抑郁普通食品,保健品或药品。
Description
技术领域
本发明涉及一种组合物,特别是一种具有改善抑郁情绪与压力应激作用的药食两用组合物及其制备方法。
背景技术
抑郁症,是一种以显著而持久的心境低落为主要临床特征的病症,同时伴有失眠,记忆缺失,饮食失调等症状,严重者可出现自杀念头和行为。据世界卫生组织统计,抑郁症已成为世界第4大疾患。抑郁症患者不能适应社会,注意力下降,是自杀的高危人群。其具体发病机制主要有如下假说:(1)压力应激假说:持续的压力应激导致下丘脑-垂体-肾上腺(HPA)轴持续激活,皮质醇(Cortisol)释放增加,作用于海马神经元的糖皮质激素受体,最终损害海马组织,导致神经元与胶质细胞坏死;(2)单胺类神经递质调控紊乱假说:神经元突触间隙内神经递质5-羟色胺、去甲肾上腺素、多巴胺、重摄取增加,含量降低,神经传导阻滞;(3)神经生长营养因子调控失常假说:抑郁症患者海马与前额皮质部位神经生长因子(NGF)与脑源性神经营养因子(BDNF)缺失,神经细胞萎缩、神经可塑性受损;(4)中枢神经炎症假说:抑郁症患者脑中炎症因子IL-1β,IL-6,TNF-α表达增加,激活HPA功能亢进,加剧抑郁。此外,炎性因子会激活色氨酸犬尿酸通路,导致去甲肾上腺素与5-羟色胺过度降解。同时,通路激活产生的喹啉酸则会激动NMDA受体,引起神经兴奋毒性,损伤海马神经元。(5)“脑-肠”轴失调假说:抑郁症患者HPA轴功能亢进,CRF增高会导致肠道粘膜壁通透性增加,使肠道致病菌易位至肠系膜淋巴结或循环系统,激活巨噬细胞,产生大量炎性因子。并进入大循环,由血脑屏障上的相应炎性因子转运体携带入脑,激活小胶质细胞,继而产生大量炎性因子,诱发中枢神经炎症。肠道炎症还可激活色氨酸犬尿酸代谢通路,使来源于食物的色氨酸代谢为犬尿酸、喹啉酸等促炎物质,降低5-羟色胺的重要合成前体色氨酸的相对含量,造成中枢5-羟色胺合成不足。脑-肠”轴失调假说综合了HPA轴过度亢进与中枢神经炎症,故而成为抑郁症研究的重要热点。(6)神经兴奋/抑制失衡假说:该假说认为,慢性压力应激持续激活大脑中边缘系统的下丘脑-垂体-肾上腺(HPA)轴,促使糖皮质激素过量释放,导致前额皮质与海马区Glu能神经元过度兴奋。Glu过度释放导致突触后AMPA谷氨酸受体下调,树突棘丢失和树突萎缩。即使压力消退,Glu能突触短期也无法恢复,LTP无法形成,突触可塑性严重受损。同时,Glu神经毒性还导致了GABA能中间神经元萎缩,削弱了其抑制HPA轴过度激活的功能而加剧上述恶性循环,最终导致突触可塑性受损,前额皮质与边缘系统尤其是海马的神经连接性降低,损害神经回路完整性,导致抑郁症的发生发展。从抑郁症众多的病理假说不难发现,抑郁症是一种十分复杂的情志疾病,压力应激导致的HPA持续激活是该病的核心作用环节。而现有的治疗抑郁症的药物,包括:三环类抗抑郁药,如丙咪嗪等;五羟色胺重摄取抑制剂,如氟西汀等;单胺氧化酶抑制剂,如苯乙肼等,均以提高神经元突触间隙神经递质的浓度,抑制神经递质的重摄取作为治疗靶点,不仅导致有30%的抑郁症病人对现有药物无效。更为严重的是,一些抗抑郁药物,例如氟西汀,长期使用后病人易于产生自杀倾向。新上市的艾司氯胺酮,也因其致幻作用和潜在的成瘾性而备受争议。
发明内容
发明目的:本发明的目的在于提供一种疗效可靠,安全性好,具有很好的改善抑郁情绪与压力应激的药食两用组合物。本发明的另一目的是提供上述组合物的制备方法和应用。
技术方案:为了实现以上目的,本发明采取的技术方案为:
一种具有改善抑郁情绪与压力应激作用的药食两用组合物,它包括下列重量份数的原料:牡蛎1~10份,陈皮0.5~5份,茯苓0.5~5份,人参0.1~1份,玫瑰花0.2~2份,黄精0.5~5份,枸杞子0.5~5份,决明子0.5~5份,菊花0.5~5份,磷脂酰丝氨酸0.01~0.1份,牛磺酸0.01~0.1份。
作为优选方案,以上所述的一种具有改善抑郁情绪与压力应激作用的药食两用组合物,它包括下列重量份数的原料:牡蛎2~5份,陈皮1~4份,茯苓1~4份,人参0.2~0.5份,玫瑰花0.5~1.5份,黄精1~4份,枸杞子1~4份,决明子1~4份,菊花1~4份,磷脂酰丝氨酸0.02~0.05份,牛磺酸0.02~0.05份。
作为优选方案,以上具有改善抑郁情绪与压力应激作用的药食两用组合物,它包括下列重量份数的原料:牡蛎5份,陈皮1份,茯苓2份,人参0.4份,玫瑰花1份,黄精2份,枸杞子3份,决明子2份,菊花2份,磷脂酰丝氨酸0.02份,牛磺酸0.1份。
作为优选方案,以上具有改善抑郁情绪与压力应激作用的药食两用组合物,它包括下列重量份数的原料:牡蛎3份,陈皮3份,茯苓1份,人参0.3份,玫瑰花3份,黄精0.5份,枸杞子2份,决明子1份,菊花3份,磷脂酰丝氨酸0.06份,牛磺酸0.03份。
作为优选方案,以上具有改善抑郁情绪与压力应激作用的药食两用组合物,它包括下列重量份数的原料:牡蛎2份,陈皮1份,茯苓1.5份,人参0.5份,玫瑰花0.5份,黄精1.5份,枸杞子1份,决明子1份,菊花1份,磷脂酰丝氨酸0.05份,牛磺酸0.05份。
本发明的创新之处:
抑郁症的产生,中医药多将其归入“郁病”“失眠”“善忘”“癫证”“百合病”“梅核气”等范畴。中医认为抑郁症多由情志所伤,五脏气血阴阳不和,脑神不利所致。情志因素是抑郁症的致病原因,而“脏气弱”是抑郁症发病的重要内在因素。其病位在脑,涉及五脏,而以心、肝、脾、肾为主。初起时以实证或虚证多见,发病日久则多虚实夹杂之证。本虚以肝肾阴亏、肾精亏虚、心脾两虚为主;标实以肝郁气滞、痰浊、血瘀为主。
长期紧张担忧,忧虑不解,或经历惊吓恐惧,而致使肾精受损;或抑郁症日久,气滞、血瘀、痰湿等实邪迁延难祛,久病及肾,从而因实致虚,导致肾精亏虚。肾主骨生髓,上充于脑,而脑髓为脑神存在的物质基础,故肾精亏虚,脑神失养,出现情绪低落,悲观失望,兴趣索然,疏懒退缩,意志减退等脑神功能低下之症状。而肝肾同源,肾精亏虚,则水不涵木,肝失疏泄,气机不畅,从而因虚致实,而形成肝气郁结。肝郁日久化火,肝火与水湿搏结,化为湿热,蕴结肝胆,则形成肝胆湿热之证。湿热相蒸,肝胆疏泄失常,则心神不宁,故急躁易怒,失眠多梦;湿热郁阻,脾胃升降失司,气血生化不足,心失所养,则致心悸、胆怯、失眠、健忘。最终形成虚实夹杂的抑郁证候,肾精亏虚为本,气机壅滞为标。治疗当注意辨别阴阳虚实,注重虚实兼顾之大法。虚证则予养心、健脾、滋肝、补肾。实证则以理气开郁,活血清热、化痰祛湿;
舒郁解压方系根据上述抑郁症的病因病机分析,结合中医临床经验,该方由枸杞子、黄精、决明子、人参、茯苓、麦芽、陈皮、玫瑰花、牡蛎、菊花组成。方中枸杞子滋肝补肾,益精填髓;黄精补脾气,益肾阴;决明子补益肝肾,三药共用,肾精得充。人参补五脏之气,助肾精化生气血,肝体得养,又兼具养心安神之效。人参又可补益脾气,茯苓渗湿健脾、宁心安神;麦芽疏肝消滞、陈皮疏肝理气、玫瑰花疏肝活血祛瘀,四药合用,肝气得疏、脾胃运化功能得复,又可防枸杞子、黄精滋腻碍胃之患。牡蛎重镇安神,潜阳补阴,功兼化痰益阴。菊花一可藉升散之性引助诸药上行,二可与牡蛎、决明子共奏清肝化火之功,并可防人参温燥伤阴。全方标本兼顾,补泻同施,补虚而不碍邪,祛邪而不伤正,诸药相协,能奏益气养阴,化痰祛瘀,安神定志之功。在此基础上,结合抑郁症的现代研究成果,加入具有促进多巴胺分泌的磷脂酰丝氨酸以及具有抗疲劳与改善抑郁症乏力核心症状的牛磺酸,可更好增强抗抑郁效用。
本发明所述的具有改善抑郁情绪与压力应激的药食两用组合物的制备方法,包括以下步骤:
(1)按重量份数取枸杞子、黄精、决明子、人参、茯苓、麦芽、陈皮、玫瑰花、牡蛎、菊花,加入药材重量5~15倍体积量的水,回流提取2~3次,每次1~2h,过滤,合并滤液;
(2)取步骤(1)的滤液,减压浓缩,按重量份数加入磷脂酰丝氨酸和牛磺酸制得组合物。
作为优选方案,步骤(1)所述的回流提取条件为:第一次加入药材重量10倍体积量的水,160℃回流提取90min。第二次和第三次加入药材重量8倍体积量的水,160℃回流提取60min。
有益效果说明:本发明提供的药食两用组合物,通过中医临床经验筛选得到。在动物模型上具有显著缓解动物抑郁样行为、抑制压力应激HPA轴激活、增加脑内神经递质与神经营养因子供给、抑制中枢神经炎症的作用。上述研究表明本发明提供的中药组合物对抑郁样情绪有显著的改善作用,同时可效改善压力应激HPA轴的激活,可用于制备具有改善抑郁情绪与压力应激作用的药食两用组合物的食品、保健品、药品或相关医药产品。
本发明所述药食两用组合物在改善抑郁情绪与压力应激中的应用,将此药食两用组合物和药学上可接受的载体制成片剂、丸剂、散剂、汤剂、颗粒剂、煎膏剂或浸膏剂剂型的产品,临床服用方便,并且本发明提供的药食两用组合物,无明显毒副作用,可长期服用,安全性好。
附图说明
图1为组合物对悬尾小鼠不动时间影响的柱状图。
图2为成分组合物对强迫游泳小鼠不动时间影响的柱状图。
图3为组合物对慢性压力应激抑郁小鼠糖水偏嗜指数影响的柱状图。
图4为组合物对慢性压力应激抑郁小鼠血清中压力因子影响的柱状图。
图5为组合物对慢性压力应激抑郁小鼠脑内神经递质影响的柱状图。
图6为组合物对慢性压力应激抑郁小鼠海马区神经营养因子影响的柱状图。
图7为组合物对慢性压力应激抑郁小鼠海马区炎性因子影响的柱状图。
具体实施方式
下面结合具体实施例进一步阐明本发明,应理解这些实施例仅用于说明本发明而不用于限制本发明的范围,在阅读了本发明之后,本领域技术人员对本发明的各种等价形式的修改均落于本申请所附权利要求所限定的范围。
实施例1一种中药组合物的制备方法,包括如下步骤:
(1)准确称取牡蛎5份,陈皮1份,茯苓2份,人参0.4份,玫瑰花1份,黄精2份,枸杞子3份,决明子2份,菊花2份。加入药材重量10倍量的水回流提取90min,过滤,收集滤液和滤渣。
(2)取步骤(1)中的药渣,加入药材重量8倍体积量的水回流提取60min,过滤,收集滤液。
(3)取步骤(2)中的药渣,加入药材重量8倍体积量的水回流提取60min,过滤,收集滤液。
(4)合并步骤(1)、步骤(2)与步骤(3)中所得滤液,减压浓缩得浸膏,加入磷脂酰丝氨酸0.02份,牛磺酸0.1份,制得药食两用组合物。
实施例2一种药食两用组合物的制备方法,包括如下步骤:
(1)准确称取牡蛎3份,陈皮3份,茯苓1份,人参0.3份,玫瑰花3份,黄精0.5份,枸杞子2份,决明子1份,菊花3份。加入药材重量10倍量的水回流提取90min,过滤,收集滤液和滤渣。
(2)取步骤(1)中的药渣,加入药材重量8倍体积量的水回流提取60min,过滤,收集滤液。
(3)取步骤(2)中的药渣,加入药材重量8倍体积量的水回流提取60min,过滤,收集滤液。
(4)合并步骤(1)、步骤(2)与步骤(3)中所得滤液,减压浓缩得浸膏,加入磷脂酰丝氨酸0.06份,牛磺酸0.03份,制得药食两用组合物。
实施例3一种药食两用组合物的制备方法,包括如下步骤:
(1)准确称取牡蛎2份,陈皮1份,茯苓1.5份,人参0.5份,玫瑰花0.5份,黄精1.5份,枸杞子1份,决明子1份,菊花1份。加入药材重量10倍量的水回流提取120min,过滤,收集滤液和滤渣。
(2)取步骤(1)中的药渣,加入药材重量6倍体积量的水回流提取120min,过滤,收集滤液。
(3)取步骤(2)中的药渣,加入药材重量8倍体积量的水回流提取60min,过滤,收集滤液。
(4)合并步骤(1)、步骤(2)与步骤(3)中所得滤液,减压浓缩得浸膏,加入磷脂酰丝氨酸0.05份,牛磺酸0.05份,制得药食两用组合物。
实施例4抗抑郁与改善压力应激实验研究
一、实验材料与药物
1.药物和试剂
氯化铝、硫酸亚铁、氢溴酸东莨菪碱、D-半乳糖酶,石杉碱甲均购自阿拉丁试剂(上海)有限公司。胆碱酯酶,SOD试剂盒购自南京建成生物工程研究所。
2.实验仪器
氟西汀购自TCI(上海)化成工业发展有限公司。受试药物:本发明实施例3制备得到的药食两用组合物。
3.实验动物
SPF级雄性昆明种小鼠,体重18~22g,购自南京中医药大学实验动物中心,合格证号SCXK(浙)2008-0033。
二、实验方法
1.慢性压力应激抑郁症小鼠模型的建立与药食两用组合物给药
动物安置7天以适应环境,进行体重与糖水偏嗜率测试,剔除数值异常的小鼠。选取测试评分正常的小鼠,随机分为6组,每组15只。组别分别为空白组、模型组、药食两用组合物低剂量组、药食两用组合物中剂量组、药食两用组合物高剂量组、氟西汀组。空白组小鼠与模型小鼠分开饲养,不给予任何刺激。模型小鼠每天随机给予不同的两种刺激,刺激方式包括:禁水24h、禁食24h、斜笼、电击、束缚4h、湿笼、昼夜颠倒。每周进行体重和糖水偏嗜测试,记录小鼠体重变化与糖水偏嗜率。持续8周,待抑郁表型出现后,对抑郁小鼠进行灌胃给药,持续7天,动物的分组和给药剂量详见表1。
表1动物分组和给药剂量
动物组别 | 给药剂量和天数 |
空白组 | 0.9%生理盐水,10天 |
模型组 | 0.9%生理盐水,10天 |
药食两用组合物低剂量组 | 1.35g/kg/d,10天 |
药食两用组合物中剂量组 | 2.70g/kg/d,10天 |
药食两用组合物高剂量组 | 4.05g/kg/d,10天 |
氟西汀组(Fluoxetine) | 7.2mg/kg/d,10天 |
2.药效评价方法
(1)行为学测试方法
糖水偏嗜实验:通过测量小鼠的蔗糖偏好和摄入量的降低来显示小鼠对奖励敏感性的变化,从而评估小鼠的抑郁程度。实验分为糖水适应阶段和测试阶段,糖水适应阶段的小鼠单笼饲养,第一天给予小鼠两瓶200ml 1%的蔗糖水溶液,适应24h后将一瓶糖水换成一瓶200ml的纯水,第三天禁食禁水,第四天正式测试阶段分别给予小鼠一瓶1%蔗糖水溶液和纯水各200ml,记录各水瓶重量。4h后记录小鼠糖水和纯水的消耗量,计算小鼠的糖水偏嗜率=糖水消耗量/(糖水消耗量+纯水消耗量)*100%。
悬尾实验:在距离小鼠尾部约1cm左右处粘贴胶布,悬挂于平台上,使其头部与实验台面约15cm,悬挂6min,小鼠以头朝下的姿势悬挂,刚开始悬挂时会进行挣扎和晃动,随之会放弃挣扎,使用ANY-MAZE软件记录小鼠在2~6min内的不动持续时间。
强迫游泳实验:将小鼠单独放置于装有干净水的圆柱玻璃缸内,保持缸内水温25℃,水深约20cm,强迫小鼠游泳6min,游泳时使小鼠后爪不能碰触水缸,小鼠的不动状态记为小鼠放弃挣扎,身体被动的漂浮在水面上,使用ANY-MAZE软件记录小鼠在2~6min内的不动持续时间。
(2)血清压力应激因子含量测定
行为学测试结束后,处死小鼠,处死动物,常规眼眶取血,常温静置2h后3500rpm/min,4℃离心,吸取血清。测定CRF、ATCH与corticosterone含量。试剂盒检测范围为7.8-500p。
(3)神经递质测定
样品处理:将完成行为学测试的慢性压力应激抑郁小鼠处死后,解剖取全脑组织,按5g/mL的浓度值加入一定体积的甲酸(0.5M),高速分散制成匀浆液,13,200转/分离心5分钟后取上清液。
液相色谱分离:层析条件:流动相:0.1%甲酸(A),乙腈+0.1%甲酸。流速:0.2ml/min。梯度条件:0.0min:99%A;2.0min:99%A;6.0min:90%A;10min:90%A。
质谱检测:干燥气温度(Drying gas temperature):325℃;干燥气流速(Dryinggas flow):10L/min;毛细管电压(Vcap):4000V;雾化电压(Nebulizer):35psig;检测极性(Polarity):Positive;扫描模式(Scan mode):多离子检测模式(MRM);检测离子对(Ionpairs detection):154.1>137.1,154.1>91.1(多巴胺);170.1>153.1,170.1>107.1(去甲肾上腺素);170.1>153.1,170.1>107.1(去甲肾上腺素);177.1>160.1,177.1>115.1(5-羟色胺);
(4)海马组织神经营养因子含量测定
行为学测试结束后,处死小鼠,解剖获得海马组织,液氮迅速冷冻,粉碎。称取相应重量组织,加入10倍体积的组织裂解液(10mM HEPES,pH 7.5,1M NaCl,1mM EDTA,1mMEGTA,0.5% Triton X-100,5mM benzamidine HCl,10μM aprotinin,10μM leupeptin),利用NGF与BDNF ELISA试剂盒,按试剂盒所列操作步骤,测定NGF与BDNF的含量。试剂盒检测范围为7.8-500pg/mL。
(5)海马区促炎物质含量测定
样品处理同上,利用LPS、IL-1β、IL-6与TNF-αELISA试剂盒,按试剂盒所列操作步骤,测定LPS、IL-1β、IL-6与TNF-α的含量。试剂盒检测范围为7.8-500pg/mL。
3.统计学处理
所有实验数据均采用SPSS18.0统计处理软件进行统计学处理,结果以±s表示,组间差异采用One way ANOVA检验,P<0.05为差异有统计学意义。
三、实验结果
1.慢性压力应激抑郁小鼠糖水偏好性测试实验结果
给药7天后,进行慢性压力应激抑郁小鼠糖水偏好性测试实验。由图1可以看出,小鼠经灌胃7天后,本发明提供的组合物可提升小鼠糖水偏好指数,与模型组相比有显著性差异(P<0.05),显示出明显的抗抑郁作用,其趋势优于阳性药氟西汀。
2.慢性压力应激抑郁小鼠悬尾测试实验结果
给药7天后,行慢性压力应激抑郁小鼠强迫游泳实验。由图2可以看出,小鼠经灌胃7天后,本发明提供的组合物可减少小鼠悬尾的不动时间,与空白组相比有显著性差异(P<0.05),其趋势与阳性药氟西汀作用相当,显示出明显的抗抑郁作用。
3.慢性压力应激抑郁小鼠强迫游泳测试实验结果
给药7天后,行慢性压力应激抑郁小鼠强迫游泳实验。由图3可以看出,小鼠经灌胃7天后,本发明提供的组合物可减少小鼠强迫游泳的不动时间,与空白组相比有显著性差异(P<0.05),其趋势与阳性药氟西汀作用相当,显示出明显的抗抑郁作用。
4.组合物对慢性压力应激抑郁小鼠血清中压力因子影响
由图4可以看出,小鼠经灌胃7天后,本发明提供的组合物中剂量与高剂量均可显著降低血清内与抑郁症发病密切相关的CRF、ACTH与Corticosterone的含量,与模型组相比有显著性差异(P<0.05)。与之相比,作用趋势与阳性药氟西汀相似。
5.组合物对慢性压力应激抑郁动物脑内神经递质影响
由图5可以看出,本发明提供的组合物中剂量与高剂量均可显著提升小鼠脑内的多巴胺,去甲肾上腺素与5-羟色胺的含量,与空白组相比有显著性差异(P<0.05)。与之相比,阳性药氟西汀仅对5-羟色胺具有显著的上调作用,本发明提供的组合物的调控神经递质作用靶点则更为广泛,可多靶点发挥治疗抑郁症的作用。
6.组合物对抑郁动物脑内神经营养因子影响
由图6可以看出,小鼠经灌胃7天后,本发明提供的组合物中剂量与高剂量均可显著提升海马组织内与抑郁症发病密切相关的BDNF、NGF的含量,与模型组相比有显著性差异(P<0.05)。与之相比,组合物可显著提升NGF作用,趋势强于氟西汀,取得了非常好的技术效果。
7.组合物对慢性压力应激抑郁小鼠海马区促炎物质影响
由图7可以看出,小鼠经灌胃7天后,本发明提供的组合物中剂量与高剂量均可显著降低海马组织内与抑郁症发病密切相关的LPS、IL-1β、IL-6、TNF-α的含量,与模型组相比有显著性差异(P<0.05)。与之相比,氟西汀难以降低LPS的表达,提示组合物具有更多的调控神经炎性因子的作用靶点,取得了非常好的技术效果。
以上实验结果表明,本发明提供的组合物具有显著的缓解动物抑郁样行为、抑制压力应激HPA轴激活、增加脑内神经递质与神经营养因子供给、抑制中枢神经炎症的作用。具有较高的食品、保健产品或药物开发价值。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (9)
1.一种具有改善抑郁情绪与压力应激作用的药食两用组合物,其特征在于,它包括下列重量份数的原料:牡蛎1~10份,陈皮0.5~5份,茯苓0.5~5份,人参0.1~1份,玫瑰花0.2~2份,黄精0.5~5份,枸杞子0.5~5份,决明子0.5~5份,菊花0.5~5份,磷脂酰丝氨酸0.01~0.1份,牛磺酸0.01~0.1份。
2.根据权利要求1所述的一种具有改善抑郁情绪与压力应激作用的药食两用组合物,其特征在于,它包括下列重量份数的原料:牡蛎2~5份,陈皮1~4份,茯苓1~4份,人参0.2~0.5份,玫瑰花0.5~1.5份,黄精1~4份,枸杞子1~4份,决明子1~4份,菊花1~4份,磷脂酰丝氨酸0.02~0.05份,牛磺酸0.02~0.05份。
3.根据权利要求1所述的一种具有改善抑郁情绪与压力应激作用的药食两用组合物,其特征在于,它包括下列重量份数的原料:牡蛎2份,陈皮1份,茯苓1.5份,人参0.4份,玫瑰花0.5份,黄精1.5份,枸杞子1份,决明子1份,菊花1份,磷脂酰丝氨酸0.05份,牛磺酸0.05份。
4.根据权利要求1所述的一种具有改善抑郁情绪与压力应激作用的药食两用组合物,其特征在于,它包括下列重量份数的原料:牡蛎5份,陈皮1份,茯苓2份,人参0.3份,玫瑰花1份,黄精2份,枸杞子3份,决明子2份,菊花2份,磷脂酰丝氨酸0.02份,牛磺酸0.1份。
5.根据权利要求1所述的一种具有改善抑郁情绪与压力应激作用的药食两用组合物,其特征在于,它包括下列重量份数的原料:牡蛎3份,陈皮3份,茯苓1份,人参0.5份,玫瑰花3份,黄精0.5份,枸杞子2份,决明子1份,菊花3份,磷脂酰丝氨酸0.06份,牛磺酸0.03份。
6.权利要求1~5任一项所述的具有改善抑郁情绪与压力应激作用的药食两用组合物的制备方法,其特征在于,包括以下步骤:
(1)按重量份数取牡蛎、陈皮、茯苓、人参、玫瑰花、黄精、枸杞子、决明子、菊花,加入药材重量5~15倍体积量的水,回流提取2~3次,每次1~2h,过滤,合并滤液;
(2)取步骤(1)的滤液,减压浓缩,按重量份数加入磷脂酰丝氨酸和牛磺酸制得组合物。
7.权利要求1至5任一项所述的具有改善抑郁情绪与压力应激作用的药食两用组合物在制备改善抑郁情绪的食品、保健品或药品中的应用。
8.根据权利要求7所述的应用,其特征在于,将组合物的提取物与食品可接受的载体制成饮料或糖果的食品。
9.根据权利要求7所述的应用,其特征在于,将组合物的提取物与药学上可接受的载体制成口服液、片剂、汤剂、颗粒剂、煎膏剂或浸膏剂的保健品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310665610.2A CN116616444A (zh) | 2023-06-07 | 2023-06-07 | 具有改善抑郁情绪与压力应激作用的药食两用组合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310665610.2A CN116616444A (zh) | 2023-06-07 | 2023-06-07 | 具有改善抑郁情绪与压力应激作用的药食两用组合物及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116616444A true CN116616444A (zh) | 2023-08-22 |
Family
ID=87602444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310665610.2A Pending CN116616444A (zh) | 2023-06-07 | 2023-06-07 | 具有改善抑郁情绪与压力应激作用的药食两用组合物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116616444A (zh) |
-
2023
- 2023-06-07 CN CN202310665610.2A patent/CN116616444A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101185699B1 (ko) | 의약품과 건강식품 제작에 개머루속 식물 및 그 추출물의응용 | |
CN112245443A (zh) | 人参皂苷Rg3与Rg5的组合物及其抗肿瘤等药用 | |
CN102120953B (zh) | 一种养生滋养干红保健酒及其应用 | |
US20210000904A1 (en) | Novel use of maydis stigma extract in prophylaxis and therapy of sleep disorder | |
CN105055855B (zh) | 具有改善睡眠、增强免疫力作用的中药组合物及其制备方法和应用 | |
CN105535425B (zh) | 一种具有增强免疫力作用的中药组合物及其制备方法与用途 | |
CN108420890B (zh) | 一种具有降血脂作用的组合物及其制备方法 | |
US9445624B2 (en) | Anti-fatigue composition of plant material and preparation method, use and products thereof | |
CN101904907A (zh) | 富含肌醇和总黄酮的荞麦提取物及其制备方法 | |
CN111513155A (zh) | 一种防治脂代谢异常的组合物 | |
CN116616444A (zh) | 具有改善抑郁情绪与压力应激作用的药食两用组合物及其制备方法与应用 | |
CN114794478A (zh) | 一种能降低血压血脂血糖的组合物及应用 | |
CN110269897B (zh) | 一种抗疲劳和改善睡眠的组合物及其用途 | |
CN111588800B (zh) | 一种中药组合物及其制备方法和应用 | |
CN103735621A (zh) | 一种具有降血脂和增强免疫力作用的中药组合物 | |
CN111053854B (zh) | 一种具有治疗抑郁症作用的中药制剂及其制备方法与应用 | |
CN108514093B (zh) | 一种辅助降血糖的多功能食品组合物及其制备方法 | |
CN102552861A (zh) | 人参四逆颗粒剂及其制备方法 | |
CN111480846A (zh) | 一种辅助降血脂、提高免疫力的保健品 | |
CN108524477A (zh) | 治疗胃肠功能紊乱或肠易激综合症的辛弗林组合物及其应用 | |
CN111053819A (zh) | 中药组合物提取物及在制备蛋白表达调节剂中的应用 | |
CN108771683A (zh) | 治疗胃肠功能紊乱或肠易激综合症的芍药苷/辛弗林组合物及其应用 | |
CN108938656A (zh) | 治疗胃肠功能紊乱或肠易激综合症的芍药苷组合物及其应用 | |
CN114869964B (zh) | 一种治疗慢性疲劳综合症的中药组合物及其制备方法 | |
US20240156889A1 (en) | A method for reducing animal weight |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |